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OBJECTIVES: To investigate the usefulness of measuring upper airway collapsibility with a negative expiratory
pressure application as a screening test for severe obstructive sleep apnea (OSA).
INTRODUCTION: OSA is a risk factor for cardiovascular disease, and it may have serious consequences. Its recognition
may have important implications during the perioperative period. Increased upper airway collapsibility is one of the
main determinants of OSA, and its evaluation could be useful for identifying this condition.
METHODS: Severe OSA and normal subjects (24 in each group) were matched by body mass index and referred to
our sleep laboratory. The subjects were enrolled in an overnight sleep study, and a diurnal negative expiratory
pressure test was performed. Flow drop (D _V) and expiratory volume were measured in the first 0.2 s (V0.2) of the
negative expiratory pressure test.
RESULTS: D _V (%) and V0.2 (%) values were statistically different between normal and OSA subjects. OSA patients
showed a greater decrease in flow than normal subjects. In addition, severely OSA patients exhaled during the first
0.2 s of the negative expiratory pressure application was an average of only 11.2% of the inspired volume compared
to 34.2% for the normal subjects. Analysis of the receiver operating characteristics showed that V0.2 (%) and D _V (%)
could accurately identify severe OSA in subjects with sensitivities of 95.8% and 91.7%, respectively, and specificities
of 95.8% and 91.7%, respectively.
CONCLUSIONS: V0.2 (%) and D _V (%) are highly accurate parameters for detecting severe OSA. The pharyngeal
collapsibility measurement, which uses negative expiratory pressure during wakefulness, is predictive of
collapsibility during sleep.
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INTRODUCTION
Obstructive sleep apnea (OSA) is characterized by
repetitive episodes of complete or partial interruption of
ventilation during sleep, which is caused by a collapse in the
upper airway. OSAs are associated with ongoing increasing
respiratory efforts, intermittent hypoxia, systemic and
pulmonary arterial blood pressure fluctuations and sleep
disruption. The prevalence of OSA, which is associated with
daytime sleepiness, is approximately 3-7% for adult men
and 2-5% for adult women in the general population.1 A
diagnosis of OSA syndrome is made when a patient has an
apnea-hypopnea index (AHI; number of apneas and
hypopneas per hour of sleep) > 5/h and symptoms of
excessive daytime sleepiness.2
OSA is an independent risk factor for cardiovascular
disease,3-4 which includes hypertension, atrial fibrillation,
coronary artery disease, and stroke. In addition, OSA has
important social implications related to road5 and occupa-
tional6-7 accidents, neuropsychological impairment,8 reduction
in the quality of life,9 and increased healthcare utilization;10-11
therefore, under-recognizing OSA may have important con-
sequences. Unfortunately, OSA diagnostic procedures are
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expensive, and predictive criteria are still unsatisfactory.
Identifying new predictive tools with extensive applications
would therefore be useful.
Increased upper airway collapsibility is one of the main
determinants for OSA,12-14 and it has been suggested that
responses to negative expiratory pressure (NEP) may reflect
upper airway collapsibility.15 The basis of the technique is to
apply a negative pressure at the start of expiration during
spontaneous breathing. In normal subjects, an increase in
expiratory flow is observed. In subjects with intrathoracic
airway obstruction, however, the flow measured under NEP
will not exceed spontaneous flow. In subjects with upper
airway collapsibility and under NEP, the flow can show a
transient decrease, which is caused by airway collapse.
NEP has been used to study upper airway properties in
subjects with obesity and OSA16-21 to evaluate if this
application could be used to predict OSA. Characteristics
of the NEP test have been evaluated by different methods,
and various AHI thresholds have been used to classify
subjects with and without OSA. With the application of NEP
during quiet breathing the flow drop during early expira-
tion is predictive of OSA. This procedure is better than
measuring an expiratory flow limitation equal to or less
than the corresponding flow in any part of the control
expired tidal volume.20 The purpose of this study was to
investigate the usefulness of measuring upper airway
collapsibility by NEP to detect severe OSA in subjects.
MATERIAL AND METHODS
Subjects
Subjects were first referred to our sleep laboratory and
evaluated with spirometry to exclude subjects with bron-
chial obstruction. Normal and severe OSA (AHI.30)2
subjects (24 in each group) were matched by body mass
index (BMI) and then recruited for this study (Table 1).
None of the subjects had major craniofacial, acute or known
chronic cardiopulmonary or neuromuscular disease. Each
patient gave informed consent, and the study protocol was
approved by the local scientific committee. Nocturnal
monitoring with a portable cardio-respiratory system22
and a diurnal NEP test performed during tidal expiration20
were performed on all subjects.
Pulmonary function tests
Pulmonary function tests were performed during the day
with a MedGraphics Elite plethysmograph (Med Graphics
Corporation; St. Paul, Minnesota, USA) according to
the guidelines of the European Respiratory Society.23
Nocturnal monitoring
Nocturnal monitoring was performed using a portable
computerized system (Somte´, Compumedics Inc.;
Abbotsford, VIC, Australia). All recordings lasted more
than 6 h. Flow was detected by a nasal cannulas connected
to a pressure transducer, and apneas and hypopneas were
visually scored. Apneas were defined as a lack of airflow or
greater than a 90% reduction in the airflow signal for at least
10 s. Hypopneas were defined as discernible reductions in
flow or thoracoabdominal movements $10 s followed by a
SaO2 decrease ($4%).
24 AHI was calculated as (apneas +
hypopneas)/h of the estimated total sleep time.
Negative Expiratory Pressure test (NEP)
Negative Expiratory Pressure test (NEP) was generated
by a Super Air Amplifier (Exair model 120021; Cincinnati,
Ohio, USA) attached to a tank of compressed air by an
electrically operated solenoid valve (Norgren Ltd model
95004; Warwickshire, UK). The valve was automatically
activated in early expiration and kept open for 2 s by
software control. A pneumotachograph (Hans Rudolph
model 3830; Kansas City, MO, USA) was connected to an
air amplifier and a mouthpiece to measure airflow ( _V) with
a pressure transducer (PCLA02X5; Sensortechnics GmbH,
Puchheim; D). The mouth pressure was measured by a
pressure transducer (PCLA0050; Sensortechnics GmbH
Puchheim; D). NEP (-10 cm H2O) was set by occluding the
pneumotachograph with a stopper and adjusting the flow of
compressed air to the air amplifier (Fig. 1).
In all subjects, NEP tests (-10 cm H2O) were performed in
a sitting position during quiet breathing with a nose clip.
During the test, care was taken to keep the neck in a neutral
position and the subjects awake. Breathing pattern stabiliza-
tion was required between two consecutive NEP tests.
Signal analysis and solenoid valve control were performed
using software developed in our laboratory written in
Labview 8.2 (National Instruments; Austin, TX, USA).
During tidal expiration, the NEP application produced an
immediate peak flow that was followed by a sudden drop by
variable degrees. Upper airway collapsibility was evaluated
by measuring the flow limitation as the flow drop (D _V) %
expressed as a percent of the peak flow immediately after
NEP application20 (Fig. 2). The minimum flow was identified
in the first 200 ms of NEP application to avoid reflex and
Table 1 – Subject anthropometric and respiratory data
according to apnea hypopnea index.
Variables AHI ,5/h (n = 24) AHI .30/h (n= 24) p
Male gender, n 19 21
Age, yr 44¡10 50¡8 0.015
Height, m 169¡8 169¡9 NS
Weight, kg 80.3¡12.5 86¡12 NS
BMI, kg/m2 28¡3.4 30¡2.6 NS
Neck, cm 40¡3.0 41¡2.8 NS
AHI, events/h 2.0¡1.4 59¡18 ,0.0001
FVC, % predicted 106¡14 97¡12 0.047
FEV1, % predicted 107¡13 96¡13 0.008
FEF25-75, % predicted 97¡22 85¡24 NS
Values are mean¡ SD; BMI = Body Mass Index; AHI = Apnea Hypopnea
Index; FVC = Forced Vital Capacity; FEV1 = Forced Expiratory Volume in
1 s; FEF25-75 = Forced Expiratory Flow between 25% and 75% of the
Forced Vital Capacity.
Table 2 - Receiver Operating Characteristic curve analysis
for NEP flow drop and expiratory volume at 0.2 s.
AHI ,5 vs. AHI .30 D _V (%) V0.2 (%)
Optimal cut-off point 70 22.2
Sensitivity, % 91.7 (73-99) 95.8 (79-100)
Specificity, % 91.7 (73-99) 95.8 (79-100)
Area under ROC curve 0.97 (0.88-0.99) 0.99 (0.90-1)
Data are presented as the mean (95% confidence interval); NEP =
Negative Expiratory Pressure; AHI = Apnea Hypopnea Index; D _V (%) =
Flow drop percent of the peak flow; V0.2 (%) = expiratory volume at 0.2 s
after NEP application in percent of the mean inspiratory volume of three
preceding breaths.
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voluntary reactions to the NEP stimulus.25 Values of D _V (%)
were calculated as the maximum of seven measurements.
Upper airway collapsibility was also evaluated by measuring
the expired volume at 0.2 s (V0.2) immediately after NEP
application (Fig. 2). These values were expressed as a percent
of the mean inspiratory volume of three breaths taken before
NEP application. Measured volumes were accepted only
when differences between inspiration and expiration for each
of the three breaths were less than 10%. Values of V0.2 were
calculated as the mean of seven measurements.
Statistical analysis
Logistic regression was used to analyze the continuous
factors with categorical responses. Receiver operating
characteristic (ROC) curves were constructed to determine
the probability of a positive result or sensitivity (true
positive rate) versus the probability of a false positive
result (false positive rate) at various levels of the measured
D _V (%) and V0.2 (%) values. These curves were used to
identify the cut-off value that yielded the largest number of
correctly classified patients (Table 2). The differences
between subjects were evaluated using the Mann-Whitney
test. Data are reported as mean ¡ SD, and a p-value ,0.05
was considered statistically significant. Statistical analysis
was performed using a commercially available software
package (JMP 8.0, SAS Institute Inc; Cary, NC, USA).
RESULTS
The anthropometric and respiratory characteristics of the
OSA and normal subjects are shown in Table 1. D _V (%) and
V0.2 (%) values were statistically different (p,0.0001)
between normal and severe OSA subjects (Fig. 3). Patients
with severe OSA had a greater decrease in flow compared to
normal subjects. In addition, severe OSA patients exhaled
during the first 0.2 s of the NEP application, which was an
average of 11.2% of the inspired volume, compared to 34.2%
for the normal subjects.
Given that OSA and normal subjects differed in age and
pulmonary function tests (FVC-forced vital capacity and
FEV1-forced expiratory volume first second), multiple
logistic regressions were performed. In these regressions,
the OSA and normal subjects were the dependent variables,
and the model age, FVC, FEV1 and the NEP parameters
[D _V (%) and V0.2 (%), one for each regression] were also
included. Both multiple logistic regressions showed that the
NEP parameters were not influenced by variables that were
not completely matched.
ROC curve analysis was performed to evaluate the
predictive effectiveness of D _V (%) and V0.2 (%) for severe
OSA identification (Fig. 4). Areas under the ROC curves
showed that V0.2 (%) and D _V (%) could very accurately
identify severe OSA subjects (0.99 and 0.97, respectively).
For V0.2 (%), its optimal ROC curve cut-off value was 22.2%,
with a sensitivity of 95.8% and a specificity of 95.8%,
whereas the optimal cut-off of D _V (%) was 70%, with a
sensitivity of 91.7% and a specificity of 91.7% (Table 2).
DISCUSSION
The current study verified the efficacy of measuring an
expired volume at 0.2 s and flow drop during NEP
application for identifying severe OSA subjects. The main
Figure 1 - Schematic representation of the negative expiratory pressure apparatus.
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finding was that upper airway collapsibility, which was
measured by an expired volume at 0.2 s and a flow drop
during NEP, is a valuable predictor for severe OSA.
Obesity and increased upper airway collapsibility are
considered among the most important determinants for
OSA. Previous studies on obese male subjects have shown
that at least 40% are affected with OSA.26-27 Given that
obesity is considered a major cause of OSA, we performed
the ROC curve analysis on the V0.2 and flow drop induced
by NEP in severe OSA and normal subjects matched for BMI
(body mass index). These results are consistent with
collapsibility being the main mechanism of upper airway
obstruction during sleep and BMI being a major factor to
precipitate upper airway collapsibility. Higher collapsibility
was associated with severe OSA, whereas lower collapsi-
bility was characteristic for normal subjects. Our data show
that upper airway collapsibility could be a useful tool to
predict severe OSA when evaluated by the NEP measure-
ments D _V and V0.2.
Previous studies have evaluated the flow limitation
induced by NEP during wakefulness by different methods
to assess upper airway collapsibility in OSA and non-OSA
subjects.16-21 Some studies have applied methods similar to
those adopted for evaluating flow limitation in patients with
bronchial obstruction;15 however, other studies have per-
formed new methods for quantifying upper airway obstruc-
tion.16-21 The different methods have shown a role for NEP in
identifying upper airway collapsibility. Van Meerhaeghe et
al.18 expressed the expiratory flow limitation as the percen-
tage of the expired tidal volume over which the NEP-induced
flow did not exceed spontaneous flow. The authors con-
cluded that NEP might be useful in predicting OSA with an
Figure 2 - Measurement techniques for upper airway collapsibility evaluated as expiratory volume in 0.2 s (percent of the mean
inspiratory volume of the three breaths preceding NEP application) and as the flow drop (D _V; expressed as the percent of the peak
flow).
Figure 3 - Comparison of the (A) flow drop percent of the peak flow D _V (%) and (B) the expiratory volume at 0.2 s [the percent of the
mean inspiratory volume V0.2 (%)] between normal and severe OSA subjects.
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AHI $15 in a clinic-based population with a sensitivity of
81.9% and a specificity of 69.1%. Tamisier et al.21 applied a
ratio of the areas under the curve for the NEP flow-volume
loop to the spontaneous flow-volume loop. They reported a
quantitative index that was higher in healthy subjects
compared to patients with any type of SDB with a reliable,
predictive positive value of 96.6% and a predictive negative
value of 76.9%. Given that sleep disorders of breathing (SDB)
and normal subjects show significant differences, there is a
trend of a lower quantitative index in severe patients who
express more highly collapsible upper airway. In our study,
we applied expiratory measurements (D _V and V0.2) at the
very beginning of expiration, showing suitable results useful
to detect upper airway obstruction.
A limitation in this study was that patients and controls
were not perfectly matched. Using multiple logistic regres-
sion analysis, however, we showed that NEP parameters
were not influenced by variables that were not completely
matched. Another limitation of this investigation was that
the population studied consisted of subjects attending a
sleep laboratory, and only severe OSA subjects were
included. This procedure was performed to better evaluate
the effectiveness of the NEP test in detecting marked upper
airway collapsibility. Further investigations on the whole
spectrum of disease severity are needed to better detect how
the NEP test could be useful in detecting mild and moderate
OSA in subjects.
OSA has been increasingly recognized as a serious health
problem worldwide. Untreated OSA in the general adult
population is significantly related to psychomotor8 and
memory28 deficits, reduced cognitive function, depressed
mood and altered quality of life in areas related to vitality,
social functioning, and mental health.9 In addition, OSA is
believed to be an independent risk factor for cardiovascular
diseases.4 Special emphasis is given to recognizing the
patient with cardiovascular disease who has coexisting
sleep apnea, which may contribute to the progression of the
cardiovascular condition. This finding may explain, at least
in part, the increased mortality rate.29
Numerous studies have found a 2- to 7-fold increase in
the risk of OSA subjects being involved in motor vehicle
crashes. The risk is more relevant for commercial motor
vehicle operators due to the weight and size of the vehicles
they drive and/or the number of passengers they trans-
port.5 It has also been shown that snoring and daytime
sleepiness, which are characteristics of OSA, are tightly
associated with occupational injuries.6-7 OSA is a treatable
risk factor, and therefore, determining its existence is
important.
With increasing diagnoses of OSA, there is an increase in
the number of people on the waiting lists for the small
number of sleep laboratories capable of clinically and
properly treating these patients. In addition, the current
diagnostic procedures are time consuming and expensive.
To address this critical issue, it is necessary to identify
reliable and inexpensive screening systems to detect
subjects at risk for the disease.
The NEP test evaluates upper airway collapsibility and
provides a rapid and objective assessment that can be
widely used to identify patients with severe OSA.
Interesting applications of this measurement could be in
assessing the fitness of drivers for specific categories, such
as commercial drivers, or identifying the perioperative
period of undiagnosed OSA patients who are known to
have a higher incidence of difficult intubations, post-
operative complications, increased intensive care unit
admissions, and an increased hospital stay. Another field
of interest could be workers with jobs who are at an
increased risk for accidents. It is important to heighten
public awareness of the potential hazards and health risks
that surround undiagnosed sleep apnea; therefore, diagnos-
ing and treating sleep apnea are important medical and
social issues.
CONCLUSIONS
In conclusion, we found that upper airway collapsibility
can be evaluated by D _V and V0.2 during the NEP test, and
these measurements are valuable to detect severe OSA
subjects. During wakefulness, the pharyngeal collapsibility
measurement using NEP is predictive of collapsibility
during sleep. The NEP test is fast and could be adopted as
a screening test for evaluating suspected, severe OSA
patients because it appears to be a very reliable diurnal test
that objectively predicts this respiratory disorder. It could be
even more powerful in association with anamnestic data,
such as snoring and hypersomnolence. Further analysis
using a more heterogeneous population could also be
useful.
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